Posaconazole liquid vs tablet formulation in lung transplant recipients
Authors:
Abstract
Summary: Posaconazole is an extended‐spectrum triazole antifungal used in the treatment and prophylaxis of Aspergillus infections. It is available as oral suspension (POS‐Liq) and delayed‐release tablets (POS‐Tab). The aim of this longitudinal, retrospective study was to compare the clinical effectiveness, toxicity and pharmacokinetics of POS‐Liq vs POS‐Tab in lung transplant recipients (LTx‐recipients), who were treated with both formulations subsequently. Twenty‐four consecutive LTx‐recipients with 191 documented posaconazole trough levels (PTLs) for POS‐Liq or POS‐Tab were included. The administered daily doses were 300 mg for POS‐Tab and 600 mg (prophylaxis) or 800 mg (therapy) for POS‐Liq. Target PTLs were ≥700 ng/mL (prophylaxis) and ≥1250 ng/mL (therapy). The overall prophylactic and therapeutic response rates were 78% and 67%, respectively. No cases of hepatotoxicity or QT‐prolongation were observed with either formulation. The achieved target PTLs were tripled under POS‐Tab compared to POS‐Liq with fewer risk factors for sub‐therapeutic PTLs. Concomitant administration of POS‐Tab significantly reduced the tacrolimus concentration‐to‐dose ratio (P = .001). We suggest the use of POS‐Tab is appropriate for prophylaxis and therapy of Aspergillus infections in LTx‐recipients, since POS‐Tab displayed more reliable PTLs with no added adverse events. However, we recommend regular drug monitoring for POS‐Liq and for therapy with POS‐Tab and that immunosuppressant levels are monitored closely when the posaconazole formulation is switched.Keywords
This publication has 37 references indexed in Scilit:
- The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summaryThe Journal of Heart and Lung Transplantation, 2016
- Suspected posaconazole toxicity in a pediatric oncology patientPediatric Blood & Cancer, 2015
- Inhibition of antifungal therapy by gastric acid suppressantsIntensive Care Medicine, 2015
- Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of PosaconazolePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report—2012The Journal of Heart and Lung Transplantation, 2012
- Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantationInternational Journal of Hematology, 2012
- Immunsuppression und Infektionsprophylaxe nach LungentransplantationPneumologie, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adultsBritish Journal of Clinical Pharmacology, 2003
- How to measure the QT interval—What is normal?The American Journal of Cardiology, 1993